We take AI drug discovery platforms into pharma.
Strong science rarely moves a pharma partnership on its own. We are the operator-led business development partner for AI drug discovery companies, run by senior operators who built and closed these deals from inside global pharma. We reach the decision-makers who are hard to reach and carry the commercial conversation through to a signed term sheet.
Navigating Pharma for AI Drug Discovery deals is a challenge
Pharma moves slowly with AI drug discovery platforms. Deal cycles run twelve to twenty-four months through internal processes an outside company cannot see into, the people who decide are hard to reach, and the evaluation is as political as it is scientific. A mid-stage platform's partnering window is usually shorter than that cycle.
Most AI drug discovery companies share the same profile: strong science, strong academic roots, a small team, a validated platform, and almost no commercial capacity to reach pharma. The conventional fix is to raise a Series A extension and spend eighteen months hiring a VP of business development and a commercial team. By the time that apparatus exists, the window has moved.
HealthSeed supports AI Drug Discovery business development
We represent AI drug discovery companies to pharma under operator credibility. When your company enters a pharma R&D conversation with us alongside you, the pharma counterpart recognises us as peers from their own career path. That recognition carries commercial value a BD boutique or a generic consultancy cannot supply.
We do not claim your IP, your molecules, or your designs. What we bring is a mapped relationship path into the right pharma R&D functions, a commercial thesis written in pharma's own vocabulary and anchored to comparable transactions, and the discipline to carry the deal through every stage gate.
CADENCETM. Proprietary HealthSeed methodology for Pharma Partnering.
CADENCE is our proprietary business development methodology, built specifically for AI drug discovery and run by operators who navigated pharma's internal processes from the inside. Each stage has defined scope, timing, and cost, and a gate that has to clear before the next begins. The full cycle runs from a named account universe to a signed term sheet in nine to eighteen months.
One pharma problem, several platforms, one offer.
Pharma R&D heads seek tailored solutions beyond what single AI Drug Discovery company can offer. We assemble complementary AI drug discovery capabilities into one integrated offering matched to a specific pipeline problem. Each company reaches a deal it could not close alone, and pharma receives a capability stack it could not assemble internally inside a twelve to eighteen month evaluation cycle.
A pharma team running an autoimmune bispecific antibody programme has a gap across four dimensions. A single CADENCE-assembled offer can combine target validation, antibody design, optimisation chemistry, and in-vivo validation, four capabilities from four companies, into one package the pharma partner buys as a unit.
Agency white-label
We assemble the capability stack and contract through a vendor that already holds pre-approved status inside pharma procurement. Pharma sees one vendor on the record.
R&D-sponsored engagement
An R&D head sponsors a capability mapped directly to a live pipeline problem. Scientific justification carries the procurement exception pathway that pharma runs routinely for differentiated capability.
Operators pharma recognises as peers.
Our founding operators built senior commercial careers across global pharma, including general management and global brand leadership. Our scientific and BD bench carries decades across global pharma and Boston biotech R&D, with direct experience in the DACH and China markets. The pharma counterpart across the table has usually walked the same path.
Basel-anchored
Scientific credibility and wet-lab validation access in one of Europe's strongest biotech ecosystems. Computational claims become biological evidence before we represent them to pharma.
Transatlantic by design
A Basel scientific anchor and a Boston node for US deal flow, so a company is represented on both sides of the Atlantic from the first conversation.
Pan-continental relationships
Working relationships with national innovation bodies and trade missions that actively route AI drug discovery companies and capital toward Europe.
We share the outcome.
A monthly retainer covers the methodology from account mapping through active outreach and partnership conversations. Commission economics activate on signed, attributed deals, and the structure is adapted per company at signing. Most of the upside sits in the deal, which puts our incentive where yours already is: getting to a signed term sheet.
Building a platform that should be in pharma?
A short call to cover your platform, your target pharma partners, and whether HealthSeed is the right business development partner.
Book a Discovery Call →Evaluating the AI-DD field?
We can map curated AI drug discovery capabilities to your pipeline gaps. Start with a conversation.
Talk to us →Or email contact@healthseed.vc directly.